| 2023-03-03 |
Aptorum International Limited |
Regulatory Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus aptorumgroup.com ↗
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions with the US Food and Drug Administration (“US FDA”). |
| 2021-07-12 |
Aptorum International Limited |
Results Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus aptorumgroup.com ↗
|
| 2021-05-24 |
Aptorum International Limited |
Results Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma aptorumgroup.com ↗
We are pleased to announce that no human subjects were dropped out of the studies and there were no Serious Adverse Events (SAE) observed. |
| 2021-01-20 |
Aptorum International Limited |
Regulatory Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) aptorumgroup.com ↗
The clearance of our CTA application for ALS-4 drug represents a significant milestone for the company and one of a number of targeted strategic goals for 2021. |
| 2020-12-21 |
Aptorum International Limited |
Regulatory Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA) aptorumgroup.com ↗
|
| 2020-09-01 |
Aptorum International Limited |
Results Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020 aptorumgroup.com ↗
As announced today, further positive data showing significant in vivo activities of ALS-4 (for MRSA wound healing and MRSA bacteraemia) and also in vitro and in vivo studies of SACT-1 (for neuroblastoma and other potential tumor types). |
| 2020-09-01 |
Aptorum International Limited |
Results Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models aptorumgroup.com ↗
|
| 2020-02-10 |
Aptorum International Limited |
Results Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020 aptorumgroup.com ↗
Subject to completion of the current studies, Aptorum Group targets to submit IND for ALS-4 in second half of 2020 and commence a phase 1 trial in North America . |